The company's shares, which have more than quadrupled this year on hopes of its vaccine working, SURGED another 18% to $15.77 early trading.
[...]
Inovio began human testing of its vaccine in April. ... Inovio said preliminary results from its human trial are expected in June. The 40 healthy participants in the Phase 1 trial are given two shots, four weeks apart, of the vaccine, called INO-4800, and then followed for two weeks.